Abstract:Background context: Spinal cord injury brings devastating consequences and huge economic burden. Different authoritative organizations have developed different guidelines for pharmacological treatments of spinal cord injury, but there is a lack of a critical appraisal of them. Purpose: To systematically review and appraise guidelines regarding their recommendations for pharmacological treatments for spinal cord injury. Study design: Systematic review. Methods: We searched Medline, Embase, Cochrane, and Web of Science from January 2000 to January 2022 as well as guideline-specific databases (eg, Congress of Neurological Surgeons) and Google Scholar. We included the most updated guideline containing evidence-based recommendations or consensus-based recommendations developed by specific authoritative organizations if multiple versions were available. We appraised guidelines through the Appraisal of Guidelines for Research and Evaluation, 2nd edition instrument consisting of six domains (eg, applicability). With supporting evidence, recommendations were classified as: for, against, neither for nor against. We utilized an evidence assessment system to categorize the quality of supporting evidence as poor, fair, or good. Results: Eight guidelines developed from 2008 to 2020 were included, but all of them scored lowest in the domain of applicability among all six domains. Twelve pharmacological agents (eg, methylprednisolone) were studied. For methylprednisolone, three guidelines (3/8=37.5%) recommended for (one evidence-based and two consensus-based), three (3/8=37.5%) recommended against (all evidence-based), and two (2/8=25%) recommended neither for nor against. For monosialotetrahexosylganglioside (GM-1), one guideline (1/4=25%) recommended for (consensus-based), one (1/4=25%) recommended against (evidence-based), and two (2/4=50%) recommended neither for nor against. For other agents (eg, minocycline), most guidelines (3/5=60%) recommended neither for nor against, one (1/5=20%) recommended against naloxone (evidence-based) and nimodipine (evidence-based), and one (1/5=20%) recommended for neural growth factor (consensus-based). The quality of most of the supporting evidence was poor, and the rest was fair. Conclusions: There were inconsistencies among recommendations for methylprednisolone and GM-1. Evidence-based recommendations tended to recommend against, whereas consensus-based recommendations tended to recommend for.

Pharmacological management of secondary chronic spinal cord injury: a systematic review

Pharmacologic Therapy for Spinal Cord Injury

Impact of commonly administered drugs on the progression of spinal cord injury: a systematic review

Acute Spinal Cord Injury: Pathophysiology and Pharmacological Intervention (Review).

Update on the treatment of spinal cord injury

An updated systematic review of neuroprotective agents in the treatment of spinal cord injury

Inflammogenesis of Secondary Spinal Cord Injury

A critical appraisal of clinical practice guidelines on pharmacological treatments for spinal cord injury

Modern Medical Management of Spinal Cord Injury

Pharmacological intervention for chronic phase of spinal cord injury

Methodology of systematic reviews and recommendations

Pharmacological and non-pharmacological therapeutic interventions for the treatment of spinal cord injury-induced pain

Do Pharmacological Treatments Act in Collaboration with Rehabilitation in Spinal Cord Injury Treatment? A Review of Preclinical Studies

Advancements in neuroregenerative and neuroprotective therapies for traumatic spinal cord injury

Management of Neuropathic Pain Associated with Spinal Cord Injury

Traumatic Spinal Cord Injury—Repair and Regeneration

Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from Phase I to II

Surgical decompression in acute spinal cord injury: A review of clinical evidence, animal model studies, and potential future directions of investigation

Research Advances Of Biomaterials-Based Microenvironment-Regulation Therapies For Repair And Regeneration Of Spinal Cord Injury

Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms

Non-invasive approaches to functional recovery after spinal cord injury: Therapeutic targets and multimodal device interventions